event
제목 Innovative drug candidate BSC-3301(RIPK1 Inhibitor)
작성자 bisichem
작성일자 2022-04-27

                                 < RIPK1 as a therapeutic target >

               

RIPK1(Receptor-interacting serine/threonine-protein kinase 1) activation in microglia

and astrocytes drives a response to inflammatory signals. RIPK1 is a critical signaling protein

in the tumor necrosis factor (TNF) receptor pathway and is a regulator of inflammation and cell death. 

RIPK1 kinase emerged the possibility to target neuroinflammation and cell death  which drive various

neurologic conditions including Alzheimer, ALS, and multiple sclerosis.



 BiSiChem has currently the following programs in development :


 BSC-3301 is an orally bioavailable, highly potent and selective, and achieving a high extent of brain-penetrating 

small molecule inhibitor in CNS diseases. RIPK1 is highly expressed by microglial cells in human AD brains.

In vivo 5XFAD model, we found that inhibition of RIPK1, using small molecule inhibitor, reduced

the levels of inflammatory cytokines and cognitive deficits.


 Non-brain penetrating RIPK1 inhibitor : BSC-1301 is an orally bioavailable small molecule for
the treatment of autoimmune diseases including psoriasis, rheumatoid arthritis (RA) and ulcerative colitis.